Cutera Receives FDA 510(k) Clearance for enlighten(TM)

First and Only FDA-Cleared Dual Wavelength and Dual Pulse Duration Laser Featuring Picosecond Technology

        Print
| Source: Cutera, Inc.

BRISBANE, Calif., Aug. 12, 2014 (GLOBE NEWSWIRE) -- Cutera, Inc. (Nasdaq:CUTR), a leading provider of laser, light and other energy-based aesthetic systems for practitioners worldwide, announced that its enlighten laser platform received U.S. Food and Drug Administration 510(k) clearance for the treatment of benign pigmented lesions. enlighten is the first and only dual wavelength (532 nm/1064 nm) and dual pulse duration picosecond laser system cleared for sale in the United States.

"The enlighten FDA clearance represents a critical milestone in bringing this industry-changing technology to market. Following the success of our excel VTM and excel HRTM laser systems, enlighten is the third and latest platform showcasing Cutera's innovations in laser and light technology, as well as advanced micro-electronics, efficient power generation, and ergonomic design.

"The system's dual wavelengths, dual pulse durations, high power, and independent adjustment of fluence and spot size are all industry-leading features that provide practitioners with the broadest range of treatment settings. Beyond the treatment of benign pigmented lesions, enlighten is pending 510(k) clearance for tattoo removal. We fully anticipate that enlighten will lead the next generation of multi-application laser platforms," said Kevin Connors, President and CEO of Cutera, Inc.

E. Victor Ross, M.D., a board certified Dermatologist at Scripps Clinic in San Diego and one of the leading experts in aesthetic laser technology commented "Picosecond pulses, which are on the order of trillionths of a second, are one of the most exciting technology innovations within the aesthetic laser and light-based industry. With enlighten, the medical community has a high power, versatile picosecond device that allows practitioners to fully leverage the clinical possibilities of extremely short pulse duration treatments. We are actively investigating how enlighten might address many skin and aesthetic concerns and look forward to moving the field forward with our research."

Commercial shipments of enlighten are anticipated to commence in the fourth quarter of 2014.

About Cutera, Inc.

Brisbane, California-based Cutera is a leading provider of laser and other energy-based aesthetic systems for practitioners worldwide. Since 1998, Cutera has been developing innovative, easy-to-use products that enable physicians and other qualified practitioners to offer safe and effective aesthetic treatments to their patients. For more information, call 1-888-4CUTERA or visit www.cutera.com.

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Specifically, statements concerning the impact of our products, expected product performance, and the anticipated benefits and market adoption of our products are forward-looking statements within the meaning of the Safe Harbor. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause Cutera's actual results to differ materially from the statements contained herein. Potential risks and uncertainties that could affect Cutera's business and cause its financial results to differ materially from those contained in the forward-looking statements include those related to the Company's efforts to improve sales productivity, hire and retain qualified sales representatives, improve revenue growth and profitability through leveraging operating expenses; the Company's ability to successfully develop and launch new products and applications and market them to both its installed base and new customers; the length of the sales cycle process; unforeseen events and circumstances relating to the Company's operations; government regulatory actions; and those other factors described in the section entitled, "Risk Factors" in its most recent Form 10-Q as filed with the Securities and Exchange Commission on August 4, 2014. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Cutera undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

Cutera, Inc.
Ron Santilli
Chief Financial Officer
415-657-5500

Investor Relations
John Mills
Integrated Corporate Relations, Inc.
310-954-1105